# Report: 0_Gliosis (run_2.md)

**Cell type:** malignant glioblastoma cells
**Disease:** glioblastoma multiforme
**Tissue:** brain

## Program Summaries
### EMT-Driven Invasion Program
A coordinated gene program mediating epithelial-mesenchymal transition and cellular invasiveness in glioblastoma. This program includes transcriptional regulators (FOSL1, KLF5, NFATC2), extracellular matrix components and remodelers (SERPINE1, COL5A1, COL6A2, COL1A2, FN1, SMOC2, ITGBL1), and cell adhesion/migration effectors (EMP1, CAV1, MYOF, KANK4, ICAM1). The program drives mesenchymal identity, enhanced cell motility, and increased invasive capacity into surrounding brain tissue.

**Predicted impacts:**
- Enhanced cell migration and invasiveness into brain parenchyma
- Increased mesenchymal identity with reduced epithelial markers
- Remodeling of focal adhesion architecture
- Facilitated ECM degradation and rearrangement
- Acquisition of stem-like properties
- Enhanced resistance to conventional therapies

**Supporting genes:** SERPINE1, EMP1, COL5A1, COL6A2, COL1A2, FN1, SMOC2, ITGBL1, FOSL1, KLF5, NFATC2, CAV1, MYOF, KANK4, ICAM1

**References:** [1], [30], [46], [5], [9]

**Biological processes:**
- transcriptional regulation of EMT: FOSL1, KLF5, NFATC2
- extracellular matrix proteolysis and remodeling: SERPINE1, COL5A1, COL6A2, COL1A2, FN1, SMOC2, ITGBL1
- cell adhesion and focal contact dynamics: ICAM1, CAV1, KANK4, MYOF

**Cellular components:**
- focal adhesions: SERPINE1, KANK4
- extracellular matrix: COL5A1, COL6A2, COL1A2, FN1, SMOC2, ITGBL1

**Reference notes:**
- SERPINE1 identified as key regulator of GBM cell dispersal and invasion
- COL5A1 promotes GBM malignancy through EMT-related mechanisms
- FOSL1 controls mesenchymal GBM plasticity and aggressiveness
- Fibronectin expression determines distinct malignant glioma progressions via TGF-β-induced EMT
- EMT in GBM progression involves TGF-β, WNT/β-catenin, and transcription factors

### Pro-Inflammatory Cytokine Signaling
A gene program centered on production and signaling of pro-inflammatory cytokines that drive GBM development and progression. This program includes IL-6, IL-8 (CXCL8), IL-1 receptor (IL1R1), IL-4 receptor (IL4R), leukemia inhibitory factor (LIF), and cardiotrophin-like cytokine factor 1 (CLCF1). These cytokines signal through receptors and downstream pathways (STAT3, NF-κB) to promote tumor cell proliferation, survival, and create an immunosuppressive microenvironment.

**Predicted impacts:**
- Enhanced proliferation via STAT3 and NF-κB activation
- Increased cell survival and reduced apoptosis
- Promotion of immunosuppressive microenvironment
- Maintenance of cancer stem cell properties
- Enhanced angiogenesis through secondary signals
- Recruitment and polarization of myeloid cells

**Supporting genes:** IL6, CXCL8, IL1R1, IL4R, LIF, CLCF1, TNFAIP3

**References:** [10], [31], [39], [4]

**Biological processes:**
- IL-6 and IL-8 production and signaling: IL6, CXCL8
- IL-1 receptor signaling and NF-κB activation: IL1R1, TNFAIP3
- LIF-mediated immunosuppression and stemness: LIF
- CLCF1-mediated cytokine signaling: CLCF1

**Cellular components:**
- cytokine receptors (gp130, IL-4R, IL-1R): IL1R1, IL4R, CLCF1

**Reference notes:**
- Comprehensive profiling of cytokine changes in GBM; IL-6 and IL-8 as key pro-inflammatory mediators
- PTX3 regulation of pro-inflammatory cytokines in GBM microenvironment
- LIF as immunosuppressive factor promoting TAM formation and cancer stemness
- CLCF1 as unfavorable prognostic marker in GBM promoting proliferation

### Angiogenesis and Vascular Signaling
A gene program driving tumor neovascularization through VEGF and apelin signaling pathways. This program includes VEGFA, APLN (apelin), CHI3L1, PTX3, and CLCF1. These genes promote endothelial cell proliferation, migration, and vascular formation, particularly under hypoxic conditions. The program creates the highly vascularized phenotype characteristic of GBM and enables nutrient delivery to support rapid tumor growth.

**Predicted impacts:**
- Enhanced vascular density and complexity within tumor
- Increased oxygen and nutrient delivery to tumor core
- Facilitation of tumor expansion into surrounding brain
- Promotion of aberrant vascular morphology (tortuous, leaky vessels)
- Enhanced BBB disruption and vasogenic edema
- Promotion of vascular-associated tumor cell invasion

**Supporting genes:** VEGFA, APLN, CHI3L1, PTX3, CLCF1

**References:** [16], [17], [21], [49]

**Biological processes:**
- VEGF-mediated endothelial proliferation and sprouting: VEGFA
- apelin-mediated sprouting angiogenesis: APLN
- CHI3L1-mediated angiogenesis: CHI3L1
- PTX3-mediated inflammation-driven angiogenesis: PTX3

**Cellular components:**
- endothelial cells and vascular structures: VEGFA, APLN, CHI3L1

**Reference notes:**
- HIF-1α and VEGF are potent biomarkers of GBM prognosis; VEGF upregulated in necrotic regions
- Apelin/APLNR signaling required for in vivo tumor angiogenesis and GBM growth
- CHI3L1 elevated in GBM serum; promotes tumor angiogenesis
- Pseudopalisades hyperexpress HIF-1 and secrete VEGF and IL-8 promoting angiogenesis

### Immune Evasion and Checkpoint Activation
A gene program enabling GBM escape from anti-tumor immune surveillance through upregulation of checkpoint ligands, immunosuppressive factors, and immune cell reprogramming mechanisms. This program includes PD-L1 (CD274), IDO1, complement factor H (CFH), and chemokines (CXCL10, CXCL14, CXCL2). These genes create an immunosuppressive microenvironment through T cell exhaustion, regulatory T cell expansion, myeloid-derived suppressor cell recruitment, and complement inhibition.

**Predicted impacts:**
- Impaired anti-tumor CD8+ T cell response
- Expansion of immunosuppressive regulatory T cells (Tregs)
- Increased immunosuppressive myeloid cell accumulation
- Enhanced complement resistance on tumor cell surface
- Reduced responsiveness to checkpoint inhibitor monotherapy
- Creation of immunosuppressive microenvironment resistant to immunotherapy

**Supporting genes:** CD274, IDO1, CFH, CXCL10, CXCL14, CXCL2, GBP2

**References:** [12], [24], [36], [8]

**Biological processes:**
- PD-L1-mediated T cell exhaustion and Treg expansion: CD274
- IDO1-mediated tryptophan depletion and immunosuppression: IDO1
- complement evasion via CFH: CFH
- chemokine-mediated immune cell recruitment and polarization: CXCL10, CXCL14, CXCL2

**Cellular components:**
- immune checkpoint molecule expression: CD274
- immunosuppressive enzyme production: IDO1

**Reference notes:**
- PD-L1 expression in GBM correlates with Treg expansion and poor prognosis
- IDO1 activation correlates with poor outcomes in GBM; immunotherapeutic targeting rationale
- CFH as innate immune checkpoint; overexpression associated with poor GBM survival
- CXCL family in high-risk gliomas with immunosuppressive microenvironment

### Extracellular Matrix Proteolysis
A gene program controlling degradation and remodeling of extracellular matrix through multiple protease systems and their regulators. This program includes serine protease inhibitors and activators (SERPINE1, SAA1, SAA2, SAA4), metalloproteinase regulators (MYOF), and cross-linking enzymes (F13A1). These genes enable ECM degradation to facilitate tumor cell migration, invasion, and colonization of brain tissue.

**Predicted impacts:**
- Increased ECM degradation facilitating invasion
- Enhanced migration through tissue barriers
- Facilitated epithelial-mesenchymal transition
- Increased availability of cryptic ECM epitopes
- Enhanced protease-mediated release of growth factors
- Support for basement membrane penetration

**Supporting genes:** SERPINE1, SAA1, SAA2, SAA4, MYOF, F13A1, ANPEP

**References:** [1], [27], [33], [42]

**Biological processes:**
- plasminogen activator system regulation: SERPINE1
- matrix metalloproteinase regulation and activation: SAA1, SAA2, SAA4, MYOF
- fibrin cross-linking and matrix stabilization: F13A1

**Cellular components:**
- serine protease inhibitors and activators: SERPINE1
- membrane trafficking and vesicular transport: MYOF

**Reference notes:**
- SERPINE1 as key regulator of ECM degradation and remodeling in GBM
- SAA induces MMP-2 and MMP-9 expression and activates ECM-degrading enzymes
- ECM actively shapes GBM tumor development through proteolytic remodeling
- F13A1 stabilizes fibrin networks in tumor microenvironment

### Glioma Stem Cell Maintenance
A gene program sustaining cancer stem cell properties including self-renewal, pluripotency, and differentiation resistance. This program includes transcriptional regulators (HMGA2, KLF5, NFATC2), anti-apoptotic factors (BAG3, BIRC3), stem cell growth factors (LIF, ANGPTL4), and markers of stemness. These genes maintain the pool of tumor-initiating cells resistant to therapy and responsible for tumor recurrence.

**Predicted impacts:**
- Enhanced self-renewal capacity of tumor-initiating cells
- Maintenance of pluripotency-related gene expression
- Increased resistance to differentiation signals
- Enhanced tumorigenicity in in vivo models
- Resistance to conventional chemotherapy and radiation
- Promotion of tumor recurrence and relapse

**Supporting genes:** HMGA2, KLF5, NFATC2, BAG3, BIRC3, LIF, ANGPTL4

**References:** [19], [23], [31], [34]

**Biological processes:**
- transcriptional regulation of stemness: HMGA2, KLF5, NFATC2
- LIF-mediated stem cell self-renewal: LIF
- ANGPTL4-mediated GSC enrichment: ANGPTL4
- anti-apoptotic signaling in stem cells: BAG3, BIRC3

**Cellular components:**
- stem cell transcriptional machinery: HMGA2, KLF5

**Reference notes:**
- HMGA2 promotes GBM stemness, invasion, and tumorigenicity
- LIF promotes cancer stem cell maintenance in GBM
- ANGPTL4 induces stemness and drug resistance in GBM
- BAG3 overexpressed in GBM and promotes cell survival

### Hypoxia Adaptation and Response
A gene program enabling GBM survival and proliferation in low-oxygen microenvironment through metabolic reprogramming and stress response mechanisms. This program includes hypoxia-regulated genes (NDRG1, IDO1), metabolic enzymes, and cell cycle regulators. These genes allow tumor cells to adapt to severe hypoxia in the tumor core and pseudopalisading regions.

**Predicted impacts:**
- Survival in severely hypoxic tumor core (0.1-1% oxygen)
- Increased tolerance to oxidative stress
- Maintenance of proliferation despite oxygen deprivation
- Enhanced invasiveness at tumor periphery
- Transition between proneural and mesenchymal states
- Support for pseudopalisade formation and function

**Supporting genes:** NDRG1, IDO1

**References:** [16], [26], [49], [50]

**Biological processes:**
- hypoxia-inducible gene expression: NDRG1
- metabolic adaptation to hypoxia: IDO1

**Cellular components:**
- hypoxia response elements in gene promoters: NDRG1

**Reference notes:**
- NDRG1 is critical for GBM survival under hypoxic stress
- HIF-1α regulates hypoxic gene expression in GBM
- Metabolic rewiring supports GBM survival in hypoxic tumor microenvironment
- Pseudopalisades are severely hypoxic regions with HIF-1 overexpression

### Macrophage/Microglia Reprogramming
A gene program recruiting and reprogramming myeloid cells toward tumor-supporting phenotypes. This program includes toll-like receptor signaling (TLR2), chemokines (CXCL10, CXCL14, CXCL2), acute-phase proteins (SAA1, SAA2, SAA4, PTX3), and cell adhesion molecules (ICAM1, CCN1). These genes create a chemotactic gradient and provide signals that convert infiltrating macrophages and microglia into immunosuppressive, pro-tumoral cells.

**Predicted impacts:**
- Increased infiltration of macrophages and microglia into tumor
- Conversion to immunosuppressive M2-like phenotype
- Enhanced production of pro-tumoral cytokines
- Increased tumor-associated macrophage (TAM)-mediated angiogenesis
- Reduced CD8+ T cell activation and function
- Enhanced tumor cell invasion and metastatic potential

**Supporting genes:** TLR2, CXCL10, CXCL14, CXCL2, SAA1, SAA2, SAA4, PTX3, ICAM1, CCN1, GBP2

**References:** [11], [27], [48], [8]

**Biological processes:**
- TLR2-mediated macrophage reprogramming: TLR2
- chemokine-mediated immune cell recruitment: CXCL10, CXCL14, CXCL2
- acute-phase protein signaling in immune cells: SAA1, SAA2, SAA4, PTX3
- cell adhesion-mediated immune-tumor interaction: ICAM1, CCN1

**Cellular components:**
- toll-like receptors: TLR2
- chemokine receptors on myeloid cells: CXCL10, CXCL14, CXCL2

**Reference notes:**
- TLR2 mediates microglia reprogramming to glioma-supportive phenotype
- CXCL family in myeloid cell recruitment and immunosuppressive microenvironment
- SAA induces immune cell chemotaxis and inflammatory activation
- GAMs undergo reprogramming in response to GBM-derived factors

### Apoptosis Resistance and Survival Signaling
A gene program preventing programmed cell death and enabling survival under stress conditions through multiple anti-apoptotic mechanisms. This program includes inhibitor of apoptosis proteins (BIRC3, BAG3), TNF-regulated factors (TNFAIP3, TNFAIP2), and cell cycle checkpoint regulators (GADD45A). These genes suppress intrinsic and extrinsic apoptotic pathways while maintaining proliferative capacity.

**Predicted impacts:**
- Resistance to intrinsic (mitochondrial) apoptosis pathway
- Reduced responsiveness to TNF-α and FAS ligand
- Enhanced survival under therapeutic stress
- Reduced sensitivity to chemotherapy and radiotherapy
- Increased cell proliferation despite damage signals
- Resistance to immunogenic cell death

**Supporting genes:** BAG3, BIRC3, TNFAIP3, TNFAIP2, GADD45A, FAS

**References:** [13], [23], [35]

**Biological processes:**
- inhibitor of apoptosis (IAP) signaling: BIRC3
- BAG3-HSP70-BAX anti-apoptotic complex formation: BAG3
- TNF-mediated survival signaling: TNFAIP3, TNFAIP2
- DNA damage response and cell cycle arrest: GADD45A

**Cellular components:**
- mitochondrial membrane and apoptosome: BAG3, BIRC3

**Reference notes:**
- BAG3 as survival factor in GBM; target for sensitizing tumors to therapy
- BIRC3 promotes high-grade glioma and reduces tumor-free survival
- TNFAIP2 knockdown induces immunogenic cell death in GBM

### Growth Factor and Receptor Signaling
A gene program coordinating mitogenic signaling through multiple growth factor receptors and their downstream effectors. This program includes receptor tyrosine kinases (MET, AXL), their ligands, and signaling molecules (SPP1, IL4R). These genes activate phosphoinositide-3-kinase/AKT/mTOR and mitogen-activated protein kinase/ERK pathways driving proliferation and survival.

**Predicted impacts:**
- Enhanced proliferation via PI3K/AKT and MAPK/ERK pathways
- Increased cell survival and apoptosis resistance
- Enhanced migration and invasion
- Increased sensitivity to growth factors
- Sustained tumorigenic signaling independent of EGFR
- Potential escape from EGFR-targeted therapies

**Supporting genes:** MET, AXL, SPP1, IL4R

**References:** [14], [15], [6]

**Biological processes:**
- HGF/MET autocrine signaling: MET
- AXL receptor tyrosine kinase signaling: AXL
- SPP1 (osteopontin)-mediated growth signaling: SPP1
- IL-4 receptor signaling: IL4R

**Cellular components:**
- receptor tyrosine kinases: MET, AXL

**Reference notes:**
- HGF/MET autocrine signaling in GBM with therapeutic implications
- AXL inhibition reduces GBM growth and invasiveness
- SPP1-mediated tumor growth through ERK/MAPK signaling

### Transcriptional Master Regulation
A gene program establishing core transcriptional networks governing GBM phenotype through master transcription factors and their regulatory complexes. This program includes FOSL1 (AP-1 family), KLF5 (zinc finger family), NFATC2 (calcineurin-dependent), and associated regulatory proteins (RCAN2). These transcription factors control chromatin accessibility and activate large cohorts of target genes driving mesenchymal identity and stemness.

**Predicted impacts:**
- Coordinate regulation of large transcriptional programs
- Maintenance of mesenchymal gene signature
- Control of chromatin accessibility at key loci
- Integration of multiple signaling inputs into transcriptional response
- Establishment of GBM subtype identity
- Resistance to differentiation signals

**Supporting genes:** FOSL1, KLF5, NFATC2, RCAN2

**References:** [22], [25], [9]

**Biological processes:**
- AP-1 transcriptional control of EMT and stemness: FOSL1
- KLF5-mediated stemness and angiogenesis: KLF5
- NFAT-dependent immune and survival signaling: NFATC2
- RCAN-mediated calcineurin regulation: RCAN2

**Cellular components:**
- chromatin regulatory complexes: FOSL1

**Reference notes:**
- FOSL1 controls GBM plasticity through chromatin remodeling and mesenchymal transcriptional control
- KLF5 as key transcription factor in cancer including GBM
- NFAT proteins in GBM progression

### Inflammatory Lipid Mediator Signaling
A gene program centered on production and signaling of arachidonic acid-derived inflammatory mediators, particularly prostaglandins. This program includes cyclooxygenase-2 (PTGS2), its target prostaglandin E2 (PGE2), and downstream signaling through EP receptors. These genes create a pro-inflammatory microenvironment promoting tumor growth and therapeutic resistance.

**Predicted impacts:**
- Increased local PGE2 concentration in tumor microenvironment
- Enhanced GBM cell proliferation via EP1 receptor
- Increased GBM cell survival and radiation resistance via EP2 and EP4
- Enhanced GBM cell migration
- Maintenance of cancer stem cell self-renewal
- Promotion of angiogenesis and immunosuppression

**Supporting genes:** PTGS2

**References:** [18], [4]

**Biological processes:**
- COX-2/PGE2 inflammatory cascade: PTGS2
- PGE2-mediated EP receptor signaling: PTGS2

**Cellular components:**
- cyclooxygenase-2 enzyme: PTGS2

**Reference notes:**
- COX-2/PGE2 signaling as alternative therapeutic target for GBM beyond COX-2 inhibition
- IL-1β upregulates COX-2 expression in GBM inflammation

### Cellularity and Structural Organization
A gene program involving structural proteins and organizational factors contributing to GBM cellularity and architectural features. This program includes ribosomal proteins (RPS5, RPS18, RPS27), cell cycle regulators, and developmental morphogens (SLIT3). These genes support basic cellular infrastructure and mass while also modulating cell behavior.

**Predicted impacts:**
- Enhanced protein synthesis capacity
- Increased ribosomal biogenesis
- Support for rapid proliferation
- Potentially altered cell morphology and migration
- Modified developmental signaling

**Supporting genes:** RPS5, RPS18, RPS27, SLIT3

**References:** [50]

**Biological processes:**
- protein synthesis and ribosome biogenesis: RPS5, RPS18, RPS27
- developmental morphogen signaling: SLIT3

**Cellular components:**
- ribosome and translational machinery: RPS5, RPS18, RPS27

**Reference notes:**
- Metabolic rewiring in GBM includes enhanced protein synthesis

### Metabolic Adaptation and Nutrient Sensing
A gene program enabling GBM cells to survive and proliferate in nutrient-poor, hypoxic tumor microenvironment through metabolic flexibility and nutrient scavenging. This program includes amino acid metabolism genes (IDO1, kynurenine pathway), lipid-handling genes (GPD1, DHRS3, LRAT), and nutrient transporters (SLC10A6, GPC5). These genes allow metabolic switching and nutrient acquisition to sustain tumor growth.

**Predicted impacts:**
- Enhanced survival in nutrient-deprived microenvironment
- Increased biosynthetic capacity for rapid proliferation
- Metabolic flexibility enabling adaptation to regional microenvironmental variations
- Simultaneous immunosuppression through tryptophan depletion
- Acquisition of lipids for membrane biogenesis and signaling
- Reduced dependence on exogenous nutrient availability

**Supporting genes:** IDO1, GPD1, DHRS3, LRAT, SLC10A6, GPC5

**References:** [12], [50]

**Biological processes:**
- tryptophan catabolism and amino acid metabolism: IDO1
- lipid metabolism and biosynthesis: GPD1, DHRS3, LRAT
- nutrient transport and scavenging: SLC10A6, GPC5

**Cellular components:**
- metabolic enzymes and transporters: IDO1, GPD1, DHRS3, LRAT

**Reference notes:**
- Comprehensive analysis of metabolic rewiring in GBM including glycolysis, glutamine, and tryptophan metabolism
- IDO1 activation in cancer metabolism and immunosuppression

### DNA Damage Response and Genomic Stability
A gene program responding to DNA damage and maintaining genomic stability under therapeutic and oxidative stress. This program includes DNA damage-inducible genes (GADD45A), cell cycle checkpoints (RRAD, NPR3), and oxidative stress responses. These genes enable GBM cells to survive DNA-damaging therapies and maintain proliferation despite accumulated genomic alterations.

**Predicted impacts:**
- Enhanced tolerance of DNA damage from radiation and chemotherapy
- Continued proliferation despite checkpoint signals
- Maintenance of genomic stability despite accumulated mutations
- Reduced sensitivity to temozolomide
- Potential development of therapeutic resistance

**Supporting genes:** GADD45A, RRAD, NPR3

**References:** [45]

**Biological processes:**
- DNA damage sensing and p53 response: GADD45A
- cell cycle checkpoint control: RRAD, NPR3

**Cellular components:**
- DNA damage sensing machinery: GADD45A

**Reference notes:**
- GADD45A plays protective role against temozolomide treatment in GBM

## References
- [1] Notes: SERPINE1 identified as key regulator of GBM cell dispersal and invasion | SERPINE1 as key regulator of ECM degradation and remodeling in GBM
- [10] Notes: PTX3 regulation of pro-inflammatory cytokines in GBM microenvironment
- [11] Notes: TLR2 mediates microglia reprogramming to glioma-supportive phenotype
- [12] Notes: IDO1 activation correlates with poor outcomes in GBM; immunotherapeutic targeting rationale | IDO1 activation in cancer metabolism and immunosuppression
- [13] Notes: BIRC3 promotes high-grade glioma and reduces tumor-free survival
- [14] Notes: AXL inhibition reduces GBM growth and invasiveness
- [15] Notes: SPP1-mediated tumor growth through ERK/MAPK signaling
- [16] Notes: HIF-1α and VEGF are potent biomarkers of GBM prognosis; VEGF upregulated in necrotic regions | HIF-1α regulates hypoxic gene expression in GBM
- [17] Notes: CHI3L1 elevated in GBM serum; promotes tumor angiogenesis
- [18] Notes: COX-2/PGE2 signaling as alternative therapeutic target for GBM beyond COX-2 inhibition
- [19] Notes: HMGA2 promotes GBM stemness, invasion, and tumorigenicity
- [21] Notes: Apelin/APLNR signaling required for in vivo tumor angiogenesis and GBM growth
- [22] Notes: KLF5 as key transcription factor in cancer including GBM
- [23] Notes: BAG3 overexpressed in GBM and promotes cell survival | BAG3 as survival factor in GBM; target for sensitizing tumors to therapy
- [24] Notes: PD-L1 expression in GBM correlates with Treg expansion and poor prognosis
- [25] Notes: NFAT proteins in GBM progression
- [26] Notes: NDRG1 is critical for GBM survival under hypoxic stress
- [27] Notes: SAA induces MMP-2 and MMP-9 expression and activates ECM-degrading enzymes | SAA induces immune cell chemotaxis and inflammatory activation
- [30] Notes: Fibronectin expression determines distinct malignant glioma progressions via TGF-β-induced EMT
- [31] Notes: LIF as immunosuppressive factor promoting TAM formation and cancer stemness | LIF promotes cancer stem cell maintenance in GBM
- [33] Notes: ECM actively shapes GBM tumor development through proteolytic remodeling
- [34] Notes: ANGPTL4 induces stemness and drug resistance in GBM
- [35] Notes: TNFAIP2 knockdown induces immunogenic cell death in GBM
- [36] Notes: CFH as innate immune checkpoint; overexpression associated with poor GBM survival
- [39] Notes: CLCF1 as unfavorable prognostic marker in GBM promoting proliferation
- [4] Notes: Comprehensive profiling of cytokine changes in GBM; IL-6 and IL-8 as key pro-inflammatory mediators | IL-1β upregulates COX-2 expression in GBM inflammation
- [42] Notes: F13A1 stabilizes fibrin networks in tumor microenvironment
- [45] Notes: GADD45A plays protective role against temozolomide treatment in GBM
- [46] Notes: EMT in GBM progression involves TGF-β, WNT/β-catenin, and transcription factors
- [48] Notes: GAMs undergo reprogramming in response to GBM-derived factors
- [49] Notes: Pseudopalisades hyperexpress HIF-1 and secrete VEGF and IL-8 promoting angiogenesis | Pseudopalisades are severely hypoxic regions with HIF-1 overexpression
- [5] Notes: COL5A1 promotes GBM malignancy through EMT-related mechanisms
- [50] Notes: Metabolic rewiring supports GBM survival in hypoxic tumor microenvironment | Metabolic rewiring in GBM includes enhanced protein synthesis | Comprehensive analysis of metabolic rewiring in GBM including glycolysis, glutamine, and tryptophan metabolism
- [6] Notes: HGF/MET autocrine signaling in GBM with therapeutic implications
- [8] Notes: CXCL family in high-risk gliomas with immunosuppressive microenvironment | CXCL family in myeloid cell recruitment and immunosuppressive microenvironment
- [9] Notes: FOSL1 controls mesenchymal GBM plasticity and aggressiveness | FOSL1 controls GBM plasticity through chromatin remodeling and mesenchymal transcriptional control
